Company intelligence / Profile preview

SynAct Pharma AB

Ownership: Private
Employees: ~6
Development stage: Phase 2

Overview

SynAct Pharma is currently conducting Phase 2 clinical trials for its lead drug candidate resomelagon (AP1189) in rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. The company recently announced the initiation of a Phase II study with resomelagon for the treatment of patients with dengue in April 2025. They also received a Notice of Allowance for a US Patent covering resomelagon combination therapy.

Therapeutic areas: ImmunologyInfectious DiseasesNephrology
Modalities: Melanocortin agonistsoral and injectable selective melanocortin agonists
Industry: Biotech

Drug pipeline

2 assets

resomelagon

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on SynAct Pharma AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SynAct Pharma AB.

Explore the full profile